FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to a method of producing a conjugate of a cell-binding agent and a cytotoxic agent. Cytotoxic agent is brought into contact with a bifunctional cross-linking reagent represented by structural formula 
or its salt in a buffer solution containing a buffer agent, wherein the buffer solution has a high buffer capacity and the molar ratio of the buffer to the bifunctional cross-linking reagent ranges from 2:1 to 8:1. Mixture containing a cytotoxic agent compound with a linker is obtained. Obtained compound is brought into contact with a cell-binding agent in a solution having pH from 4 to 9. Second mixture containing a conjugate of a cell-binding agent and a cytotoxic agent are obtained.
EFFECT: invention leads to considerable reduction of antibody fragmentation and increases stability of prepared conjugates.
70 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| USE OF PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT - CYTOTOXIC AGENT CONJUGATES | 2013 |
|
RU2661083C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
